Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMS12U
|
|||
| Drug Name |
Brazikumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 3 | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [2] | ||
| Company |
AstraZeneca
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03961815) An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04277546) A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE). U.S.National Institutes of Health. | |||
| REF 3 | Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.